Our findings provide new insights into the mechanism by which PART1 promotes HCC development of HCC and suggest that the PART1/miR-490-3p/SLC7A11 axis is a potential diagnostic biomarker and therapeutic target for HCC, which functions by modulating ferroptosis. Here, PART1 is linked to hepatocellular carcinoma.